These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8260750)

  • 1. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
    Haldane A; Finlay GJ; Baguley BC
    Oncol Res; 1993; 5(3):133-8. PubMed ID: 8260750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
    Bridewell DJ; Finlay GJ; Baguley BC
    Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
    Finlay GJ; Atwell GJ; Baguley BC
    Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells.
    Kim D; Lee IS; Jung JH; Lee CO; Choi SU
    Anticancer Res; 1999; 19(5B):4085-90. PubMed ID: 10628358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
    Holm C; Covey JM; Kerrigan D; Pommier Y
    Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.
    Haldane A; Holdaway KM; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1993; 32(6):463-70. PubMed ID: 8258195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
    Bridewell DJ; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
    Beck WT; Danks MK
    Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
    Adjei AA; Charron M; Rowinsky EK; Svingen PA; Miller J; Reid JM; Sebolt-Leopold J; Ames MM; Kaufmann SH
    Clin Cancer Res; 1998 Mar; 4(3):683-91. PubMed ID: 9533538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
    Woynarowski JM; McCarthy K; Reynolds B; Beerman TA; Denny WA
    Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
    Sorensen M; Sehested M; Jensen PB
    Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.
    Spicer JA; Finlay GJ; Baguley BC; Velea L; Graves DE; Denny WA
    Anticancer Drug Des; 1999 Feb; 14(1):37-45. PubMed ID: 10363026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
    Finlay GJ; Riou JF; Baguley BC
    Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
    Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
    J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
    Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
    Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
    Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
    Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
    Haldane A; Finlay GJ; Hay MP; Denny WA; Baguley BC
    Anticancer Drug Des; 1999 Jun; 14(3):275-80. PubMed ID: 10500502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
    Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines].
    Takigawa N; Ohnoshi T; Ueoka H; Yonei T; Kiura K; Tabata M; Kodani T; Kamei H; Segawa Y; Shibayama T
    Gan To Kagaku Ryoho; 1993 May; 20(7):929-35. PubMed ID: 8387762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.